about
Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patientsPharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsEfficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled TrialCCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans.Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan AfricaEvaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.Effect of Rumex Abyssinicus on preneoplastic lesions in dimethylhydrazine induced colon carcinogenesis in ratsEthics in global health research: the need for balanceGenome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.Mycobacterium tuberculosis in central Ethiopia: drug sensitivity patterns and association with genotype.Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa.Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injuryKeratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine.β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans.Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort studyEstablishment of a Sentinel Laboratory-Based Antimicrobial Resistance Surveillance Network in Ethiopia
P50
Q28472348-228E0CDE-2EE3-40FA-B66D-AAD40C81C9B4Q28478275-56BA7A48-F510-4FF4-BCA0-0ED16F4C5EFCQ28551970-53066462-6435-495A-A3FF-B0462054957FQ35039268-12FA1554-28D5-486F-B98B-E3F13BA6DD00Q35046564-647ECAC1-FDE3-4AC7-AF65-A1D241EE5473Q35142786-8585C43D-B847-4DD8-8A7B-B4BC17E369F5Q35598520-B9367BE4-B515-4C1F-A1A3-46129149FCCCQ35809179-249470FF-2545-46C0-9952-73EFCA5B0EA0Q36035798-8B521CEE-7489-4062-B983-528E88B3A149Q36145491-CEF2EC2D-AEB2-49AE-BC55-89699F474520Q37667333-2C028067-B3EE-49D7-B3E7-6344F440991AQ37725239-3BEC6155-480C-4075-9E6C-84728E49BF60Q38371653-AAE688C0-EF60-43CB-862F-1E9A63B2BCF7Q38733565-3E16AE4A-8BA1-458B-9CCB-F0BC728A2430Q39039468-E5D70320-1F62-498A-AB49-23B9F8E3F6B7Q40563423-E35D5CDC-9612-427F-A530-8CA585D9DE56Q40694902-8066050F-132B-4CC6-AB25-934AE61A42C9Q40736165-B6CB5C65-57EB-48E3-B4BD-BEC9E8B0E846Q42263059-B804576A-4040-4D1C-9438-2B2371FBEF52Q43927522-DF80C86F-00FC-40EB-A486-DCCFEF8C885FQ43938608-6631591F-F44F-4D38-A4B9-7C2EFC9822EAQ44132038-E9528D2E-8640-4C7C-A6C1-59C120E3A5E8Q44281312-FF4E7EC8-D13C-4A92-8FF8-1E6A027A3797Q56829831-1F98A804-B2AC-4C06-B4DC-ED0398CDAF0BQ64135452-5D9960B8-352E-47ED-859F-55A93ACC82ED
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Getnet Yimer
@ast
Getnet Yimer
@en
Getnet Yimer
@es
Getnet Yimer
@nl
type
label
Getnet Yimer
@ast
Getnet Yimer
@en
Getnet Yimer
@es
Getnet Yimer
@nl
prefLabel
Getnet Yimer
@ast
Getnet Yimer
@en
Getnet Yimer
@es
Getnet Yimer
@nl
P106
P31
P496
0000-0002-1469-837X